title: Drug transporters in breast cancer: response to anthracyclines and taxanes.
abstract: Despite the advances that have taken place in the past decade, including the development of novel molecular targeted agents, cytotoxic chemotherapy remains the mainstay of cancer treatment. In breast cancer, anthracyclines and taxanes are the two main chemotherapeutic options used on a routine basis. Although effective, their usefulness is limited by the inevitable development of resistance, a lack of response to drug-induced cancer cell death. A large body of research has resulted in the characterization of a plethora of mechanisms involved in resistance; ATP-binding cassette transporter proteins, through their function in xenobiotic clearance, play an important role in resistance. We review here the current evidence for drug transporters as biomarkers and the benefit of adding drug transporter modulators to conventional chemotherapy.
authors: a ¹ Department of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark.
authors: Iben
authors: I
authors: Kümler
authors: Jan
authors: J
authors: Stenvang
authors: José
authors: J
authors: Moreira
authors: Nils
authors: N
authors: Brünner
authors: Dorte Lisbet
authors: DL
authors: Nielsen
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000378:metabolism; D018943:Anthracyclines / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy; D043823:Taxoids / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D018528:ATP-Binding Cassette Transporters; D018943:Anthracyclines; D000970:Antineoplastic Agents; D043823:Taxoids
keywords: anthracyclines; breast cancer; drug transporters; multidrug resistance; taxanes